Patents by Inventor Daniel K. Treiber
Daniel K. Treiber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10641776Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide, wherein the target macromolecule may be a chimeric protein expressed by and within an intact viable cell and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation.Type: GrantFiled: February 16, 2018Date of Patent: May 5, 2020Assignee: Eurofins Discoverx CorporationInventors: Daniel K. Treiber, Elena Menichelli
-
Patent number: 10324092Abstract: Provided herein are nucleic acid tags that are linked to, or capable of linking to, a protein of interest. In particular, the nucleic acid tags are oligonucleotides comprising a reporter function and a protein tagging function. Also provided herein, are nucleic acid tag compositions, kits and methods of use thereof.Type: GrantFiled: July 28, 2015Date of Patent: June 18, 2019Assignee: Eurofins DiscoverX CorporationInventors: Pietro Ciceri, Jeremy Hunt, Jean-Michel A. Lelias, Mike Morrison, Daniel K. Treiber, Lisa Wodicka
-
Publication number: 20180275133Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide, wherein the target macromolecule may be a chimeric protein expressed by and within an intact viable cell and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation.Type: ApplicationFiled: February 16, 2018Publication date: September 27, 2018Inventors: Daniel K. Treiber, Elena Menichelli
-
Patent number: 9618516Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation. This signal indicates a differential between denatured and non-denatured target macromolecules and thereby indicates a differential between target macromolecules not bound to the compound and target macromolecules bound to the compound, respectively.Type: GrantFiled: August 19, 2015Date of Patent: April 11, 2017Assignee: DISCOVERX CORPORATIONInventors: Daniel K. Treiber, Elena Menichelli
-
Publication number: 20160054322Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation. This signal indicates a differential between denatured and non-denatured target macromolecules and thereby indicates a differential between target macromolecules not bound to the compound and target macromolecules bound to the compound, respectively.Type: ApplicationFiled: August 19, 2015Publication date: February 25, 2016Inventors: Daniel K. Treiber, Elena Menichelli
-
Publication number: 20150377886Abstract: Provided herein are nucleic acid tags that are linked to, or capable of linking to, a protein of interest. In particular, the nucleic acid tags are oligonucleotides comprising a reporter function and a protein tagging function. Also provided herein, are nucleic acid tag compositions, kits and methods of use thereof.Type: ApplicationFiled: July 28, 2015Publication date: December 31, 2015Inventors: Pietro Ciceri, Jeremy Hunt, Jean-Michel A. Lelias, Mike Morrison, Daniel K. Treiber, Lisa Wodicka
-
Publication number: 20110294782Abstract: The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering small molecule p21-activated kinase (PAK) inhibitors to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides specific small molecule PAK inhibitors and pharmaceutical compositions comprising small molecule PAK inhibitors.Type: ApplicationFiled: November 9, 2007Publication date: December 1, 2011Applicant: Massachusetts Institute of TechnologyInventors: Susumu Tonegawa, Mansuo L. Hayashi, Mazen Karaman, Patrick P. Zarrinkar, Daniel K. Treiber
-
Patent number: 7323490Abstract: The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.Type: GrantFiled: May 17, 2004Date of Patent: January 29, 2008Assignee: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Zdravko V. Milanov, Shamal Anil Mehta, Patrick Parvis Zarrinkar, William H. Biggs, III, Pietro Ciceri, Miles A. Fabian, Daniel K. Treiber
-
Publication number: 20040259880Abstract: The invention provides pyrrole-containing compounds and methods of use thereof. Kits and pharmaceutical compositions comprising the pyrrole compounds of the invention are also provided. The compounds and compositions disclosed herein are preferably used in the treatment of neurodegenerative diseases, cardiovascular diseases, proliferative diseases, and visual disorders. In particular, methods and compositions for the treatment of stroke are disclosed herein.Type: ApplicationFiled: May 18, 2004Publication date: December 23, 2004Applicant: Ambit Biosciences CorporationInventors: David J. Lockhart, Hitesh K. Patel, Zdravko V. Milanov, Shamal Anil Mehta, Patrick Parvis Zarrinkar, William H. Biggs, Pietro Ciceri, Miles A. Fabian, Daniel K. Treiber
-
Publication number: 20040009470Abstract: The invention provides an affinity filter for the binding of phage-displayed proteins to dissolved target molecules. The phage-displayed proteins are contacted with immobilized target in the presence and absence of dissolved target; the behavior of the phage-displayed proteins as a function of concentration of dissolved target permits approximation of the affinity of the phage-displayed protein for target. The invention also provides a method to screen large numbers of compounds for their ability to compete with a compound known to bind a phage-displayed protein.Type: ApplicationFiled: April 2, 2003Publication date: January 15, 2004Inventors: David J. Lockhart, Daniel K. Treiber, Patrick P. Zarrinkar